Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Number and Volume of Demyelinative Plaques Can Predict the Response to Treatment in Patients With Multiple Sclerosis



Hekmatnia A1 ; Etemadifar M2 ; Ghazavi A3 ; Hekmatnia F4 ; Radmard AR5 ; Shahkarami SMA6
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Radiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Department of Radiology, School of Medicine And Student Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran
  4. 4. London University, London, United Kingdom
  5. 5. Isfahan, Iran
  6. 6. Department of Pediatrics, School of Medicine And Student Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran

Source: Journal of Isfahan Medical School Published:2011

Abstract

Background: Interferon β (IFN- β) has been proved as an effective treatment for relapsing-remitting type of multiple sclerosis (MS), however not all patients respond to this treatment. The aims of the present study were to assess the changes in number and volume of demyelinating plaques on magnetic resonance imaging (MRI) as surrogate markers for response to IFN-β treatment in patients with relapsing- remitting MS after one year of follow-up. Methods: 41 patients with relapsing-remitting MS were recruited and IFN β-1-a treatment was started for them. Brain MRI were obtained at baseline and after one year of treatment. The number of plaques (NP) and volume of plaques (VP) were determined. The criterion for response to treatment on MRI was defined as 50% decrease in mean NP or VP. Findings: There was a significant decrease in the NP and VP after treatment (P < 0.001). The cut-off point defined for analyzing the data was 50% decrease in mean NP or VP.The specificity of NP and VP as two criteria was the same and equals to 100%. The sensitivity of the NP was 65.5% and that for VP was 90.6%. Furthermore, if the cut-off point for the NP is set at 10%, the sensitivity of NP as a criterion will be the same as that of VP (90.6%). Conclusion: These data suggest that both the NP and VP could be two reliable imaging criteria for the assessment of response to treatment on MRI. However, the VP was more accurate than the NP. © 2011, Isfahan University of Medical Sciences(IUMS). All rights reserved.
Related Docs
View other Related Docs
1. A Report of Multiple Sclerosis Patients Treated by Cinnovex™ in Iran, Tehran University Medical Journal (2010)
2. Antibodies to Interferon Beta in Patients With Multiple Sclerosis Receiving Cinnovex, Rebif, and Betaferon, Journal of Korean Medical Science (2013)
3. Rapid Exacerbation of Multiple Sclerosis Following the Initiation of Interferon-Β: Report of Nine Cases, Journal of Research in Medical Sciences (2011)
4. Comparison of Betaferon, Avonex, and Rebif in Treatment of Relapsing-Remitting Multiple Sclerosis, Acta Neurologica Scandinavica (2006)
5. Efficacy and Safety of Peginterferon Beta-1A Compared to Interferon Beta-1A in Relapsing Remitting Multiple Sclerosis Patients: A Phase 3, Randomized, Non-Inferiority Clinical Trial (Pegintegrity), Multiple Sclerosis and Related Disorders (2024)
6. Mycophenolate Mofetil in Combination With Interferon Beta-1A in the Treatment of Relapsing-Remitting Multiple Sclerosis: A Preliminary Study, Journal of Research in Medical Sciences (2011)
7. Interdependency of Ninj2 Gene Expression and Polymorphism With Susceptibility and Response to Interferon Beta in Patients With Multiple Sclerosis, International Journal of Neuroscience (2024)
8. Combination Therapy With Mitoxantrone and Plasma Exchange in Aggressive Relapsing Remitting Multiple Sclerosis: A Preliminary Clinical Study, Journal of Research in Medical Sciences (2012)
Experts (# of related papers)
View all Related Experts
Vahid Shaygannejad (66)
Masoud Etemadifar (65)
Other Related Docs
9. Neutralizing Antibodies in Multiple Sclerosis Patients on Weekly Intramuscular Avonex and Biosimilar Interferon Beta-1A (Cinnovex): Comparing Results of Measurements in Two Different Laboratories, Journal of Immunological Methods (2013)
10. Comparison of Interferon Beta Products and Azathioprine in the Treatment of Relapsing-Remitting Multiple Sclerosis, Journal of Neurology (2007)
11. Investigating the Occurrence of Femoral Head Avascular Necrosis in Patient With Multiple Sclerosis Treated With Interferon-Beta, Journal of Isfahan Medical School (2018)
12. Designing of an Elisa Method for the Measurement of Serum Antibodies Against Interferon-Beta and the Study of the Frequency of These Antibodies in Patients With Multiple Sclerosis Treated With Cinnovex, Journal of Isfahan Medical School (2012)
13. Neutralizing Antibody Production Against Rebif® and Recigen® in Relapsing-Remitting Multiple Sclerosis (Rrms) Patients and Its Association With Patient's Disability, International Immunopharmacology (2018)
14. Comparison of Susceptibility Weighted Imaging With Conventional Mri Sequences in Multiple Sclerosis Plaque Assessment: A Cross-Sectional Study, Journal of Research in Medical Sciences (2021)
15. Detection of Multiple Sclerosis Lesions by Susceptibility-Weighted Imaging—A Systematic Review and Meta-Analyses, Clinical Radiology (2024)
16. An Interdependence Between Gapvd1 Gene Polymorphism, Expression Level and Response to Interferon Beta in Patients With Multiple Sclerosis, Journal of Neuroimmunology (2021)
17. Efficacy of Adding Vitamin D Supplementation to Interferon Β-1 in Multiple Sclerosis, Journal of Isfahan Medical School (2016)
18. The Effect of Ifn-Β Treatment on Plasma Levels of Bdnf and Il-6 in Relapsing-Remitting Multiple Sclerosis Patients, NeuroImmunoModulation (2021)
19. First-Year Treatment Response Predicts the Following 5-Year Disease Course in Patients With Relapsing-Remitting Multiple Sclerosis, Neurotherapeutics (2025)
20. Effectiveness of Multiple Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis: Causal Inference to Emulate a Multiarm Randomised Trial, Journal of Neurology, Neurosurgery and Psychiatry (2023)
21. Interferon-Beta in Pediatric Multiple Sclerosis Patients: Safety in Short-Term Prescription, Acta Medica Iranica (2012)
22. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis, JAMA - Journal of the American Medical Association (2019)
23. Prevalence of Familial Multiple Sclerosis in Isfahan, Iran, Journal of Isfahan Medical School (2011)
24. Comparison of the Efficacy and Side Effects of Ifn Beta 1-A (Rebif) and a Biosimilar Product (Recigen) in Patients With Multiple Sclerosis, Journal of Isfahan Medical School (2012)
25. Concurrent Glioma and Multiple Sclerosis: A Systematic Review of Case Reports, Multiple Sclerosis and Related Disorders (2024)
26. Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis: A Randomized Clinical Trial, Acta Neurologica Scandinavica (2021)
27. Comparison of Susceptibility-Weighted Imaging With Contrast Enhancement in Detection of Multiple Sclerosis Active Plaques Using 1.5 Tesla Magnetic Resonance Imaging System, Journal of Isfahan Medical School (2017)
28. Evaluation of Plasma Soluble Cd137 Level in Relapsing-Remitting Multiple Sclerosis Patients in Comparison With Healthy Controls in Isfahan Province, Iran, Neurology Asia (2020)
29. Mir-145 and Mir20a-5P Potentially Mediate Pleiotropic Effects of Interferon-Beta Through Mitogen-Activated Protein Kinase Signaling Pathway in Multiple Sclerosis Patients, Journal of Molecular Neuroscience (2017)
30. Promising Effect of Rapamycin on Multiple Sclerosis, Multiple Sclerosis and Related Disorders (2018)
31. Neurological Efficacy and Safety of Mesenchymal Stem Cells (Mscs) Therapy in People With Multiple Sclerosis (Pwms): An Updated Systematic Review and Meta-Analysis, Multiple Sclerosis and Related Disorders (2024)
32. The Effect of Interferon-Beta Therapy on T-Helper 17/Mir-326 and T-Helper 1/Mir-29B-3P Axis in Relapsing-Remitting Multiple Sclerosis Patients, NeuroImmunoModulation (2022)
33. Lncrnas Associated With Multiple Sclerosis Expressed in the Th1 Cell Lineage, Journal of Cellular Physiology (2019)
34. The Comparative Analysis of Serum Levels of Midkine in Patients With Multiple Sclerosis and Control Group, Journal of Isfahan Medical School (2013)
35. Thalamic Asymmetry in Multiple Sclerosis, Multiple Sclerosis and Related Disorders (2023)
36. Prognostic Value of Intrathecal Igg Synthesis in Multiple Sclerosis: A Study in 54 Patients, Tehran University Medical Journal (2008)
37. Serum Uric Acid Level in Patients With Relapsing-Remitting Multiple Sclerosis, Journal of Clinical Neuroscience (2013)
38. Prescription Trends of Disease-Modifying Treatments for Multiple Sclerosis in Iran Over the Past 30 Years, Multiple Sclerosis and Related Disorders (2022)
39. Effect of Deep Gray Matter Atrophy on Information Processing Speed in Early Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis and Related Disorders (2023)
40. Joint Application of Magnetic Resonance Imaging and Biochemical Biomarkers in Diagnosis of Multiple Sclerosis, Current Medicinal Chemistry (2020)
41. The Effectiveness of Natalizumab Vs Fingolimod–A Comparison of International Registry Studies, Multiple Sclerosis and Related Disorders (2021)
42. Multiple Sclerosis: Pathophysiology, Clinical Features, Diagnosis, and Management, Neuroinflammation (2011)
43. “Nmda Receptor Spectrum Disorder” in the Differential Diagnosis of Demyelinating Disorders of the Cns: Optic Neuritis and Myelitis, Neurological Sciences (2021)
44. Connection of Mir-185 and Mir-320A Expression Levels With Response to Interferon-Beta in Multiple Sclerosis Patients, Multiple Sclerosis and Related Disorders (2020)
45. Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years, Neurology (2021)
46. Prevalence of Cognitive Impairment (Ci) in Patients With Multiple Sclerosis (Ms): A Systematic Review and Meta-Analysis, Caspian Journal of Internal Medicine (2024)
47. Safety of Sinopharm Vaccine for People With Multiple Sclerosis: Study of Adverse Reactions and Disease Activity, Multiple Sclerosis and Related Disorders (2022)
48. Evaluation of the Expressed Mir‑129 and Mir‑549A in Patients With Multiple Sclerosis, Advanced Biomedical Research (2021)
49. Late-Onset Multiple Sclerosis in Iran: A Report on Demographic and Disease Characteristics, Multiple Sclerosis and Related Disorders (2023)
50. The Serum Level of Midkine in Patients With Multiple Sclerosis and Neuromyelitis Optica, Basic and Clinical Neuroscience (2021)